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ABSTRACT  
Background and aims:  Unlike tobacco, the effect of marijuana smoke on subclinical 
atherosclerosis, a surrogate measure for cardiovascular disease, is not known.  This study 
aimed to determine the association between lifetime exposure to marijuana and measures of 
subclinical atherosclerosis in mid-life. 
Design, setting and participants: We used data from the US-based Coronary Artery Risk 
Development in Young Adults (CARDIA) Study, a cohort of black and white men and women 
aged 18-30 years at baseline in 1985-86, with up to 7 follow-up exams over 25 years.  The 
number of CARDIA participants included in this study was 3,498.   
Measurements: Cumulative years of exposure to marijuana (expressed in ‘marijuana-years’, 
with 1 marijuana-year equivalent to 365 days of use) using repeated assessments every 2-5 
years, over 25 years.  Abdominal artery calcium (AAC) and coronary artery calcium (CAC) 
scores measured by computed tomography at Year 25 exam. 
Results: Among 3,117 participants with AAC and CAC measurements, 2,627 (84%) 
reported past marijuana use and 1,536 (49%) past daily tobacco smoking. Compared with 
tobacco smokers, of which 46% reported 10 or more pack-years of use, only 12% of 
marijuana users reported 5 or more marijuana-years of use and only 6% reported having 
used marijuana daily. We found a significant interaction between never- and ever- tobacco 
users on the association between cumulative marijuana use and AAC (p=0.05). Among 
those who never smoked tobacco, cumulative marijuana-years were not associated with 
AAC or CAC in models adjusted for demographics, cardiovascular risk factors, licit and illicit 
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drug exposure and depression symptoms. However, among ever tobacco smokers, 
marijuana exposure was associated with AAC and CAC. At 5 marijuana-years of exposure, 
using AAC=0 and CAC=0 as a reference group, the odds ratio (OR) was 1.97 (95%CI:1.21-
3.21,p=0.007) for AAC>0/CAC=0 and 1.83 (95%CI:1.02-3.31,p=0.04) for CAC>0, regardless 
of AAC. Tobacco smoking was strongly associated with both AAC and CAC. 
Conclusion: Marijuana use appears to be associated with subclinical atherosclerosis, but 
only among ever tobacco users. 
 
Keywords: Marijuana, tobacco, abdominal aorto-iliac calcium, coronary artery calcium  
 
 
As marijuana use is increasingly legalized and prescribed for medical conditions, the public 
health community’s interest in informing the public about potential health effects of marijuana 
use has also grown.(1) In 2013, annual prevalence of marijuana use was 7.5 to 9.4 percent 
in the U.S. population.(2, 3)  In 2014, up to 17% of the US population smoked tobacco. 
Marijuana and tobacco smoke share many constituents.(4) Whereas the negative health 
effects of tobacco smoke are widely known,(5)  per recent National Academy of Science 
report there is little information about possible adverse health consequences of marijuana, 
including the harm prolonged and heavy use might cause to the cardiovascular system.(6, 7) 
Computed tomography can detect atherosclerosis before clinical symptoms appear 
which makes it a measure of subclinical atherosclerosis. Abdominal aorto-iliac calcium 
(AAC) and coronary artery calcium (CAC) scores are better predictors of incident coronary 
heart disease and cardiovascular disease (CVD) than standard risk factors and other well-
known biomarkers.(8, 9) Tobacco smoke is a known cause of atherosclerosis and tobacco 
use is also a strong predictor of AAC and CAC.(10) However, we do not know yet if 
marijuana smoke also causes atherosclerosis and we found only one  previous prospective 
cohort study which has assessed the association between cumulative marijuana use and 
CAC.(11) Cumulative smoking and marijuana use were significantly associated with multiple 
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plaque measures, but with negligible effect sizes for marijuana.(11) To the best of our 
knowledge, no previous study has tested the association between cumulative marijuana use 
and AAC. 
On the basis of case reports, some have voiced concern that increased marijuana 
use may  spur a new CVD epidemic.(12) Cohort studies can better isolate the possible 
association of marijuana with CVD. A large cohort of 49 321 conscripted Swedish men aged 
18 to 20 at the time of inclusion and followed over 40 years found a trend towards increased 
risk of stroke in heavy marijuana smokers after multivariate adjustment.(13) However, 
investigators only collected data on marijuana use at the time of inclusion which might have 
led to imprecise estimates of the true marijuana exposure and explain the null findings. In 
contrast, marijuana and tobacco smoking and other covariates associated with marijuana 
use and atherosclerosis have been measured repeatedly in CARDIA participants for 25 
years.  
We tested the association between cumulative marijuana use and ACC and CAC 
measures, and accounted for cumulative tobacco exposure, and other measures associated 
with atherosclerosis and marijuana and tobacco use.  
 
METHODS 
Study Design and Sample 
We used data collected over 25 years in the Coronary Artery Risk Development in Young 
Adults (CARDIA) study, a population-based epidemiological study of 5,115 adults aged 18 to 
30 years at baseline.(14) Participants were recruited in 1985 and 1986 by randomly 
selecting telephone numbers from designated census tracts in Birmingham, AL; Chicago, IL; 
Minneapolis, MN; and, by random selection from the membership list of a health care plan in 
Oakland, CA. The sampling scheme was designed to achieve equal proportions at each of 
the four sites by race (self-identified “black, not Hispanic” and “white, not Hispanic”), sex, 
education (up to a high school degree, education beyond high school), and age (18-24 
years, 25-30 years). All subjects gave informed consent before entering the study, and at 
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each follow-up examination. The study was approved by institutional review boards for each 
site. 
Marijuana and Tobacco Smoking Exposure 
Current marijuana use was assessed at each in-person CARDIA examination (at baseline 
and at 2, 5, 7,10,15, 20, and 25 years of follow-up) by the following survey question: “During 
the last 30 days, on how many days did you use marijuana?” Direct self-reported lifetime 
exposure was assessed by the question: “About how many times in your lifetime have you 
used marijuana?” We used current and lifetime use to compute marijuana-years: one year of 
exposure was equivalent to 365 days of marijuana use.(15) We assumed that current use at 
each survey (i.e., the number of days the participant used marijuana in the month before 
each survey) reflected the average number of days of use in the months between surveys. 
We estimated cumulative lifetime use by adding up the total number of days the participant 
used marijuana over the entire follow-up period. We adjusted our estimate upwards 
whenever participants self-reported higher lifetime use than we computed.(15, 16)  
Cigarette smoking behavior was evaluated at each in-person CARDIA examination, 
and at yearly phone follow-up between CARDIA examinations.(15) At baseline, participants 
were asked the total number of years they had smoked, the age at which they started 
smoking regularly (“How old were you when you started smoking cigarettes regularly?”) and, 
if appropriate, years since cessation (“How many years ago did you stop?”). We used these 
data to estimate cumulative lifetime exposure to cigarettes in terms of pack-years: one pack-
year of exposure was equivalent to 7300 cigarettes (1 year×365 days/y×1 pack/d×20 
cigarettes/pack).(15, 16) Occasional smoking was not queried in CARDIA. 
Outcome Measures: Coronary artery calcium and abdominal aortic calcium 
The primary outcome variables were presence of CAC and AAC (total calcification score > 0 
Agatston units) measured at year 25.(17) We used computed tomography (CT) to assess 
subclinical coronary atherosclerosis (presence of any CAC or AAC at year 25 [2010–
2011]).(18) To measure CAC, we obtained contiguous 2.5-3-mm-thick transverse images 
  
This article is protected by copyright. All rights reserved. 
from the root of the aorta to the apex of the heart.(19) To measure AAC, we obtained 1-1.25-
mm-thick transverse images 15-cm proximal to the superior end plate of the sacrum.(19) We 
measured calcium in the wall of the distal abdominal aorta in a 60-mm segment centered at 
the aortic bifurcation. Images collected at each center were then transmitted electronically to 
the CARDIA Reading Center.(18) Total CAC and AAC scores were calculated by image 
analysts blinded to participant characteristics; they used a modified Agatston method, with 
select over-reading by a physician expert in cardiovascular imaging.  
Other Covariates 
We estimated cumulative years of exposure to passive smoking. We defined one year of 
exposure to passive smoking as the total number of hours exposed to passive smoking over 
24h, for 365 days (eMethods in Online Data Supplements).(20) We estimated lifetime 
alcohol consumption in “drink-years.” We defined one drink-year as the amount of alcohol 
consumed by a person in one year of drinking one drink/day (eMethods).(15) We defined 
acute heavy exposure to alcohol (bingeing) as five or more drinks consumed on one 
occasion, and we estimated total lifetime bingeing episodes. We estimated total number of 
lifetime exposures to cocaine (including crack, powder, free base), amphetamines (speed, 
uppers, methamphetamines), and heroin (eMethods).(15, 21)  
The highest educational grade attained for each participant was the measure of education. 
We measured physical activity with the CARDIA Physical Activity History questionnaire, 
which asks how much time per week the participant spent in 13 categories of leisure, 
occupational, and household physical activities over the past 12 months.(22) We measured 
self-reported depressive symptoms every five years, starting at Year 5, on the Center for 
Epidemiologic Studies Depression scale (CES-D).(23) Our cardiovascular risk factor 
measurements included blood pressure, blood cholesterol (total-, LDL-, HDL-cholesterol and 
triglycerides), fasting glucose and body mass index (BMI) which were collected at each 
CARDIA exam (eMethods). We calculated cumulative exposures to cardiovascular risk 
factors, physical activity and depression symptoms (eMethods).(15, 24)  
Statistical analyses 
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We used descriptive statistics to compare participants with different levels of marijuana 
exposure at Year 25. We then described unadjusted associations between lifetime marijuana 
use and presence or absence of AAC or CAC. In our primary analysis, we used multinomial 
regression models to assess independent associations between years of exposure to 
marijuana. We compared three categories of subclinical atherosclerosis: 1) no AAC and no 
CAC; 2) any AAC and no CAC; and, 3) CAC, regardless of AAC. We found history of 
exposure to tobacco smoking significantly interacted with the association between 
cumulative exposure to marijuana and AAC, in both unadjusted and multivariate adjusted 
multinomial regression models (P=<0.1) (eTable 2). We therefore stratified all results and 
analyses by history of exposure to tobacco smoking. First, we estimated unadjusted models. 
Then, we estimated multivariate adjusted models, controlling for covariates to achieve 
balanced sampling in CARDIA (age, race, sex, study site and years of education) and for 
covariates potentially associated with both marijuana and subclinical atherosclerosis 
(cigarette smoking, alcohol, cocaine, amphetamines and heroin, exposure to passive 
smoking, cardiovascular risk factors, physical activity, BMI, depression symptoms, and 
diabetes). We used restricted cubic splines with three knots at the quartiles of their 
distributions to flexibly model marijuana-years of exposure, pack-years, and years of 
exposure to passive smoking. We used inverse probability of censoring weights (IPCWs) to 
minimize potential bias by informative censoring (eMethods).(25, 26) We tested whether sex 
and race interacted, and evaluated the sensitivity of the results to alternate strategies for 
modeling subclinical atherosclerosis using multivariate adjusted logistic regression models to 
contrast (a) participants with and without AAC, (b) those with and without CAC and, (c) those 
with AAC and CAC and those with no AAC and no CAC. We tested sensitivity of the results 
to alternate modeling techniques: 1) A multivariate adjusted model that included an 
interaction term between history of exposure to tobacco smoking and cumulative exposure 
to marijuana; 2) a multivariate adjusted model that compared participants according to 
history of exposure to marijuana and tobacco (a) no history of exposure to tobacco or 
marijuana, b) history of exposure to tobacco and not to marijuana, c) no history of exposure 
  
This article is protected by copyright. All rights reserved. 
to tobacco and history of exposure to marijuana, and d) history of exposure to both tobacco 
and marijuana; 3) a set of multivariate regressions that enabled us to model AAC and CAC 
as continuous measures (eMethods). We further evaluated the proportion of participants 
who might have been mixing tobacco with marijuana to smoke marijuana (mulling) at 
baseline by measuring blood cotinine levels, and then we tested the sensitivity of the results 
to excluding participants with cotinine levels suggestive of tobacco exposure and no self-
reported use of tobacco at baseline (eMethods).(27-29) Tests of statistical significance were 
2-tailed; alpha level was 0.05. All analyses were conducted with STATA 14.2 (StataCorp LP, 
College Station, TX).   
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RESULTS 
Of the 3,498 participants assessed at the Year 25 visit, 3,197 (91%) had data entries for 
AAC or CAC, and 3,117 (89%) had complete AAC and CAC data (eFigure 1 in Online Data 
Supplements). Attrition was more common among men, Blacks, heavy marijuana users, 
tobacco smokers, and cocaine users in multivariate adjusted analyses (eResults). In 
unadjusted analyses, attrition was associated with age, race, gender, education, and 
smoking (eTable1 in Online Data Supplements). Most participants (n=2627,84%) reported 
having used marijuana before or during the 25 years of follow-up, but most had relatively few 
cumulative years of exposure (Table 1). Among marijuana users, a minority (n=156, 6%) 
reported having used marijuana every day in the month before a CARDIA exam. Among 
those, the median number of joints smoked per day at the Year 10 exam was 2 (interquartile 
range: 1 to 3). In contrast, 1,536 (49%) reported ever smoking tobacco daily. Cumulative 
exposure to tobacco was high; 42% of ever smokers reported smoking 10 pack-years. Total 
years of marijuana exposure was strongly associated with other participant characteristics, 
including race and sex, education, study site, other substance use, physical activity, BMI, 
HDL-cholesterol and triglycerides, and depressive symptoms (Table 1). Among those who 
never smoked tobacco, 73% (N=1,155) were ever marijuana users; among ever tobacco 
smokers, 96% (N=1,472) were ever marijuana users (Table 1).  
Among those who never smoked tobacco, cumulative marijuana-years were 
associated with CAC in unadjusted analyses, but not with AAC (Table 2). Multivariate 
adjusted multinomial models that categorized presence and absence of AAC and CAC into 
three categories: AAC=0 & CAC=0, AAC>0 & CAC=0, CAC>0, regardless of AAC revealed 
lifetime exposure to marijuana was not associated AAC and CAC (Table 3 and Figure 1, 
Panels A and B). Only 26 participants were exposed to marijuana for 10 marijuana-years 
(equivalent to using marijuana every day for 10 years, or four a week for 14 years): their OR 
for CAC regardless of AAC was 1.63 (95% confidence internals (CI):0.81-3.29;Table 3). 
Among those who ever smoked tobacco daily, cumulative marijuana-years were 
associated with AAC and CAC in unadjusted analyses (Table 2). In multivariate logistic 
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regression models, at one year of exposure to marijuana, the OR for AAC and no CAC was 
1.36 (95%CI:1.07-1.71) and CAC regardless of AAC was 1.29 (95%CI:0.98-1.69;Table 
3,Figure 1,Panels C and D). In multivariate logistic regression models that compared AAC 
with no AAC, cumulative marijuana use was associated with AAC only among ever tobacco 
smokers (Table 4). Sensitivity analyses demonstrated no evidence of significant interactions 
by race or sex (p>0.10 for all tests). Results were similar when we included an interaction 
term between history of exposure to tobacco smoking and cumulative exposure to 
marijuana, instead of stratifying results by history of exposure to tobacco (eTable 2). We 
found no association between AAC or CAC and history of exposure to marijuana among 
those with no history of exposure to tobacco, and found significant associations among 
those with history of exposure to marijuana and tobacco (eTable2 in Online Data 
Supplements). Modeling AAC or CAC as continuous outcomes resulted in OR similar to 
those returned by the main models (eTable 4).  
Tobacco smoking was strongly associated with both AAC and CAC in unadjusted 
and multivariate adjusted analyses. The OR at 10 pack-years of tobacco was 5.86 
(95%CI:3.64-9.45) for AAC and no CAC and 6.61 (95%CI:3.92-11.14) for CAC regardless of 
AAC (Table 3,Figure 1,Panels E and F). 
Among participants who reported no tobacco smoking at baseline, 4% had cotinine 
levels suggestive of exposure to tobacco among those reporting no marijuana use within the 
last 30 days and 11% among those reporting marijuana use within the last 30 days (eTable). 
Results were virtually unchanged when we excluded participants with cotinine levels 
suggestive of exposure to tobacco exposure and no self-reported use of tobacco (eTable 6).   
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DISCUSSION 
In this community-based cohort of young adults, followed for 25 years, we found little or no 
significant association between cumulative marijuana use and either AAC or CAC. Among 
those who had never used tobacco, marijuana use was not significantly associated with AAC 
or CAC, but we identified a trend towards increased risk of AAC and CAC among those 
whose cumulative exposure to marijuana was high (5 marijuana-years, equivalent to 
smoking marijuana daily for 5 years). Among ever tobacco smokers, using marijuana daily 
for five years nearly doubled the odds of AAC and CAC. As expected, cumulative tobacco 
smoking exposure was strongly associated with both AAC and CAC. The vast majority of 
participants had been exposed to marijuana in their lifetime, but few had more than 365 days 
of cumulative exposure, and few used it daily. In contrast, half of participants reported they 
had smoked tobacco daily, and most had smoked 20 cigarettes a day for at least 5 years.  
Previous analyses of the participants in CARDIA study showed no association 
between marijuana use and cardiovascular events, or mortality overall.(30, 31)  One 
possibility for such lack of association was hypothesized to be due to the mean age of 
participants (around 50), which is younger than the age at which most CVD occurs. 
Therefore, our current study is able to provide timely insight on any relationship of marijuana 
with subclinical atherosclerosis.  
We found only one previous study which had tested the association between CAC 
and cumulative marijuana use, and found no previous studies having tested the association 
with AAC.(11) The 1005 participants in the Multicenter AIDS Cohort Study (MACS) 
participants (621 HIV+ and 384 HIV-) underwent non-contrast CT scanning to measure CAC 
when they were aged 54, on average. Participants were queried on self-reported use of 
substances at semiannual visits over 10 years. Cumulative pack-years of smoking and 
marijuana were significantly associated with multiple plaque measures, but with negligible 
effect sizes for marijuana.(11) Our null finding among never tobacco users could be 
explained by the opposing effects marijuana may have on atherosclerosis.(32) Besides the 
combustion constituents of marijuana smoke,(4) the main component of marijuana smoke is 
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tetrahydrocannabinol (THC), which activates the CB2 and CB1 receptors of the 
endocannabinoid system. Activating the CB2 receptor might protect marijuana smokers from 
developing atherosclerosis, since this regulates inflammatory cells and been shown to 
reduce atherosclerosis in mice.(33) Activating the CB1 receptor, on the other hand, might 
increase atherosclerosis(34) since inhibiting CB1 might protect against atherosclerosis.(35, 
36) The trend toward increasing atherosclerosis that we found among those whose 
cumulative exposure to marijuana was high might be caused by combustion constituents of 
marijuana smoke other than THC.(4, 37) In the CARDIA cohort, cumulative marijuana 
exposure was low among those who had used the drug—much lower than cumulative 
tobacco exposure among ever tobacco users. Our null findings might thus also be explained 
by the low intensity of marijuana use in our cohort. It remains possible that smoking 
marijuana every day over many years could cause as much harm as smoking tobacco 
cigarettes.  
Acute exposure to marijuana might have negative effects on heart disease since it 
can increase heart rate and could trigger arrhythmias by activating the CB1 receptor and 
precipitating an MI.(38, 39) The acute effect of marijuana might explain one study’s finding of 
a surge in MI just after marijuana use.(39) The absence of evidence of an increase in 
subclinical atherosclerosis in our study and the absence of significant association with CVD 
events in previous analyses in CARDIA,(30) suggest that even if marijuana can trigger an 
acute MI, it is does not increase the atherosclerotic process that leads to MI.  
Our study also has some limitations.  We found cumulative marijuana use was 
significantly associated with ACC among ever tobacco smokers, but we cannot rule out 
residual confounding by tobacco smoking. Tobacco smokers who use marijuana might also 
be more likely to smoke a mix of tobacco and marijuana (‘mulling’).(28, 29) When we 
explored the associations between blood cotinine levels based on self-reported exposure to 
tobacco and marijuana smoking, we found 7% of participants not reporting smoking tobacco 
might have been mulling at baseline (11% in those not reporting currently using marijuana 
vs. 4% in those reporting currently using marijuana). Blood cotinine was only measured at 
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baseline, so we cannot estimate the prevalence of mulling over follow-up or estimate the 
amount of mulling among participants who reported tobacco use. Our marijuana exposure 
measurements are derived from self-reports, which are less reliable than blood or urine 
tests. Marijuana use was measured infrequently; examinations can be up to five years apart, 
and this reduced the precision of the estimates. CARDIA also did not ask how old 
participants were when they began using marijuana, so we only could estimate exposure 
before the start of the study by looking at participants’ own estimates of the number of times 
they had been exposed to marijuana. 
Our study was strengthened by extensive adjustment for a wide range of potential 
confounders, and by particularly detailed data on primary and secondary tobacco exposure 
and other licit and illicit drug exposures. We also used advanced methods to adjust for 
cardiovascular risk factors in our models of cumulative exposures. The proportion of 
participants followed up to 25 years was high, and our statistical methods took into account 
potential informative censoring.(25, 26) Though it was difficult to fully adjust for tobacco 
exposure, because many participants said they had not smoked tobacco in their lifetime, we 
could test the association in those who only used marijuana. We had data on AAC and CAC 
scores, which are among the strongest predictors of incident coronary heart disease.(8, 40, 
41)  
Our results mostly apply to occasional, recreational users of marijuana whose 
exposure is low overall. Larger studies with longer follow-up are needed to confirm absence 
or presence of association between marijuana and subclinical atherosclerosis and CVD 
events. It would be useful to explore the trend towards increased odds of AAC and CAC with 
high cumulative use of only marijuana, based on data from large cohorts, rigorous 
measures, and extensive follow-up. If the trend is real, it may have implications for medical 
marijuana users, since they often use marijuana daily over many years. These studies are 
urgently needed to inform medical marijuana patients and prescribers about possible CVD 
risks associated with smoking medical marijuana.  
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Marijuana and tobacco use were both common, but the intensity of lifetime tobacco 
smoking was consistently much higher than marijuana. Cumulative marijuana use was not 
associated with measures of atherosclerosis among middle-aged adults never exposed to 
tobacco, but we saw a trend towards increased risk of atherosclerosis among those with 
very high exposure to marijuana. These results should be interpreted carefully since few 
participants had such high exposure. Among those who had used tobacco, we found a small 
but significant association between marijuana use and AAC, even after we extensively 
adjusted for tobacco smoke exposure, but this may have been due to residual confounding. 
Our study confirms the strong and consistent association between tobacco use and both 
AAC and CAC; the broader public health implications of high prevalence of tobacco use 
among marijuana users is alarming.  
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Panel A and B. Marijuana-years among never tobacco smokers (N=1581). 
 
Panel C and D. Marijuana-years among ever tobacco smokers (N=1536). 
 
Panel E and F. Tobacco pack-years among ever smokers (N=1536). 
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Figure 1: Associations between cumulative exposures to marijuana and tobacco and AAC and CAC. Multivariate adjusted multinomial logistic 
regression models showing an absence of association between higher exposure to marijuana and greater odds of AAC > 0 & CAC = 0 (Panel A) and CAC > 
0, regardless of ACC (Panel B) compared to AAC=0 and CAC=0 among never tobacco smokers. Among ever tobacco smokers, models show a significant 
association between higher exposure to marijuana for AAC > 0 & CAC = 0 (Panel C), but not for CAC > 0, regardless of ACC (Panel D) compared to AAC=0 
and CAC=0. For tobacco pack-years of exposure, models show a significant and dose-response association for both AAC > 0 & CAC = 0 (Panel E), and CAC 
> 0, regardless of ACC (Panel F) compared to AAC=0 and CAC=0. Scale of the axis presenting the Odds ratio multiplied by 10 to present the association with 
tobacco pack-years. Multivariate models adjusted for covariates potentially associated with marijuana, tobacco and subclinical atherosclerosis: age, race, sex, 
study site, years of education, exposure to illicit and licit substances (alcohol, cocaine, amphetamines and heroin use, exposure to passive smoking), 
cardiovascular risk factors, physical activity, BMI, depression symptoms, and diabetes (Methods). Analyses were weighted by the inverse probability of 
censoring (IPCW) to address potential bias by informative censoring (eMethods). 
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Table 1. Characteristics of 3117 CARDIA Participants with CAC and AAC measures at the Year 25 Exam, by Never/Ever Tobacco Use and 
Cumulative Marijuana Use. 
 
Never Tobacco Smoker 
N=1581 (51%) 
Ever Tobacco Smoker 
N=1536 (49%) 
 
No 
marijuana 
use 
>0 to <1 
marijuana-
years 
>1 
marijuana-
years 
No 
marijuana 
use 
>0 to <1  
marijuana-
years 
>1 
marijuana-
years 
N, (row %)‡ 426 (14) 947 (30) 208 (7) 64 (2) 787 (25) 685 (22) 
Demographics  
   - Age,  mean (SD), y 
 
49.6 (3.9) 
 
50.1 (3.6) 
 
50.9 (3.4) 
 
50.3 (3.8) 
 
50.5 (3.6) 
 
50.0 (3.6) 
   - Race-sex, N (col. %)§ 
      Black women 
 
155 (36) 
 
274 (29) 
 
31 (15) 
 
27 (42) 
 
256 (33) 
 
150 (22) 
      Black men 65 (15) 130 (14) 57 (27)  15 (23) 112 (14) 207 (30) 
      White women 102 (24) 300 (32) 41 (20) 14 (22) 278 (35)    134 (20) 
      White men 104 (24) 243 (26) 79 (38) 8 (13) 141 (18) 194 (28) 
   - Years of education, median (Q1, 
Q3), y 16 (14, 18) 16 (15, 18) 16 (14, 17) 16 (12, 18) 15 (14, 17) 14 (14, 16) 
   - Study center, N (col. %) 
      Birmingham, AL 
 
185 (43) 
 
192 (20) 
 
24 (12) 
 
35 (55) 
 
183 (23) 
 
 111 (16) 
      Chicago, IL 111 (26) 211 (22) 33 (16) 11 (17) 189 (24)  152 (22) 
      Minneapolis, MI 81 (19) 209 (22) 65 (31) 13 (20) 222 (28) 235 (34) 
      Oakland, CA 49 (12) 335 (35) 86 (41)   5 (8) 193 (25) 187 (27) 
Substance use exposure 
Current marijuana use, N (col. %)ll 
    - No current use 
 
 
426 (100) 
 
 
932 (98) 
 
 
139 (67) 
 
 
64 (100) 
 
 
762 (97) 
 
 
425 (62) 
    - 1-10 days per month - 15 (2) 34 (17) - 25 (3) 138 (20) 
    - 11 to 29 days per month - 0 (0) 26 (13) -      0 (0)   71 (10) 
    - 30 days per month (everyday)  - 0 (0) 9 (4) -   0 (0) 51 (7) 
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Cigarette smoking, N (col. %) 
    - Current smoker 
 
- 
 
- 
 
- 
 
17 (26) 
 
222 (28) 
 
314 (46) 
    - Former smoker - - - 47 (73) 565 (72) 371 (54) 
    - Age started smoking cigarettes, 
median (Q1, Q3) 
- - - 
22 (17, 32) 17 (15, 21) 17 (15, 19) 
  Cumulative use  
   - Pack-years over lifetime, median 
(Q1, Q3)¶ 
 
- 
 
- 
 
- 2 (0.3, 11) 6 (1, 14) 10 (3, 21) 
Passive smoke exposure 
   - Years of passive smoke exposure, 
median (Q1, Q3)# 
 
0.5 (0.2,1.2) 
 
0.6 (0.2,1.3) 
 
0.8 (0.4,1.8) 1.1 (0.5,2.6) 1.7 (0.6,3.5) 2.6 (1.2,5.1) 
Alcohol use, N (col. %)** 
    Cumulative use 
    - Drink-years among ever drinkers,  
      median (Q1, Q3)†† 
 
 
8 (3, 16) 
 
 
13 (6, 24) 
 
 
22 (11, 37) 
 
8 (3, 27) 
 
19 (9, 32) 
 
29 (15, 57) 
    - Binge drinking days, cumulative 
use, N (col %)‡‡ 
       - Never reported bingeing 
 
 
350 (82) 
 
 
551 (59) 
 
 
60 (29) 
 
 
44 (69) 
 
 
310 (40) 
 
 
130 (19) 
       - ≤ 250 days 51 (12) 251 (26) 64 (30)  11 (17) 259 (33) 199 (29) 
       - > 250 days 25 (6) 145 (15) 84 (40) 9 (14) 218 (28) 356 (52) 
Cumulative illicit drug use§§ 
    - Cocaine, crack, speed  
      or metamphetamine, N (col. %) 
       - Never reported using 
 
 
 
417 (98) 
 
 
 
602 (64) 
 
 
 
31 (15) 
 
 
 
60 (94) 
 
 
 
274 (35) 
 
 
 
57 (8) 
       - 1 to 25 days 7 (2) 219 (23) 45 (22) 2 (3) 232 (30) 96 (14) 
       - > 25 to 250 days 1 (<1) 100 (10) 77 (37) 1 (2) 167 (21) 223 (33) 
       - > 250 days 1 (<1) 26 (3) 55 (26) 1 (2) 114 (14) 309 (45) 
    - Heroin, N (col. %)       
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       - Never reported using 414 (97) 897 (95) 157 (75) 63 (98) 672 (85) 467 (68) 
       - 1- 25 days 10 (2) 41 (4) 31 (15)     0 (0) 74 (9) 89 (13) 
       - ≥ 25 days 2 (<1) 9 (1) 20 (10)      1 (2) 41 (5) 129 (19) 
Physical activity 
    - Physical activity score, median 
(Q1, Q3)llll 
 
234 (82, 
427) 
 
269 (143, 
490) 
 
393 (215, 
601) 
166 (49, 
315) 
268 (121, 
471) 
298 (144, 
487) 
Anthropomorphic variables 
    - BMI, mean (SD)¶¶ 
 
31.9 (7.3) 
 
30.0 (7.3) 
 
30.0 (5.9) 
 
29.5 (7.1) 
 
30.3 (7.4) 
 
29.7 (6.6) 
Cardiovascular risk factors 
    - Systolic blood pressure, mean 
(SD), in mmHg 
 
120 (16) 
 
118 (15) 
 
120 (16) 120 (18) 120 (17) 122 (16) 
    - Diastolic blood pressure, mean 
(SD), in mmHg 75 (11) 74 (11) 75 (12) 75 (12) 75 (11) 77 (11) 
    - LDL-cholesterol, mean (SD), in 
mg/dl 114 (33) 113 (31) 115 (34) 112 (36) 112 (35) 110 (32) 
    - HDL-cholesterol, mean (SD), in 
mg/dl 55 (15) 59 (18) 55 (16) 57 (21) 60 (19) 57 (19) 
    - Triglycerides, mean (SD), in mg/dl 
108 (73) 108 (76) 120 (79) 111 (64) 115 (97) 126 (106) 
    - Diabetes, N ( %) 58 (14) 112 (12) 23 (11) 11 (17) 132 (17) 89 (13) 
Psychological variables  
    - Depression symptoms, current 
CES-D ≥16/60, N (%)## 
 
59 (14) 
 
111 (12) 
 
32 (15) 10 (16) 134 (17) 131 (19) 
 
Abbreviations: BMI: body mass index; CARDIA, Coronary Artery Risk Development in Young Adults study; CES-D: Center for Epidemiologic Studies Depression scale; Col. %: 
column percent; LDL: low density lipoprotein (LDL); HDL: high density lipoprotein; N: number of participants; Q1, Q3: 1st and 3rd quartile (percentile 25 and 75); SD, standard 
deviation  
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* Cumulative lifetime exposure to marijuana joints in terms of marijuana-years, with 1 marijuana-year of exposure equivalent to 365 days used marijuana (1 year × 365 days/y) 
(see Methods and eMethods in Online Data Supplements).(16, 42)  
‡ Row percent are presented for binary variables and column percents for variables with more than one category. 
§ By design, the CARDIA study sampled self-identified white men, white women, black men and black women in roughly equal numbers for participation in the study.(43) 
ll Categories based on the answer to the question: “During the last 30 days, on how many days did you use marijuana?” 
¶ Cumulative lifetime exposure to cigarettes in terms of pack-years, with 1 pack-year of exposure equivalent to 7300 cigarettes (1 year × 365 days/y × 1 pack/d × 20 
cigarettes/pack)(Methods).(16) 
# Cumulative lifetime exposure to second hand cigarette smoke in terms of years of second hand smoking 
 exposure with 1 year of exposure equivalent to 8700 hours of exposure (1 year × 365 days/y × 24 hours per day)(Methods).(20) 
†† Drink-years among those reporting ever drinking alcohol. A drink-year was defined as the total amount of ethanol consumed by a person who had one alcoholic drink per day 
for 1 year (1 drink-year = 17.24 ml of ethanol/drink × 1 drink/day × 365 days/year = 6,292.6 ml of ethanol). 
‡‡ Binge-drinking days defined as 5 or more drinks per episode (eMethods in Online Data Supplements). If bingeing were to be constant over 25 years in one individual, 250 
binge drinking days would correspond to 10 episodes of bingeing per year over 25 years.  
§§ The number of days on the illicit drug listed over the study duration was computed using current exposure (current use defined as any use within the last 30 days) at each 
visit and replaced by lifetime exposure when the latter was higher. Cocaine included other forms of cocaine such as crack, powder, free base; amphetamines included 
speed, uppers and methamphetamines (Methods and eMethods in Online Data Supplements).  
llll Physical activity measured with the CARDIA Physical Activity History questionnaire, which queries the amount of time per week spent in 13 categories of leisure, 
occupational, and household physical activities over the past 12 months.(22) 
¶¶ Calculated as weight in kilograms divided by height in meters squared. 
## Depression symptoms was measured every five years starting at the Year 5 visit by using the Center for Epidemiologic Studies Depression scale (CES-D).(23) A score of 
≥16 used as the cut-off value for both sexes as an indication of the clinically significant depressive symptoms.(44) 
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Table 2. Association between life-time exposure to marijuana and measures of subclinical atherosclerosis among never and ever tobacco users, CARDIA, 
year 25 
 
 Total 
 Never Tobacco smoker p-value†  Ever Tobacco smoker p-
value† 
  
Total No 
marijuana 
use 
>0 to <1 
marijuana-
years 
>1 
marijuana-
years 
  
Total No 
marijuana 
use 
>0 to <1 
marijuana-
years 
>1 
marijuana-
years 
  
N, (col %) 3117 (100) 1581(100) 426 (100) 947 (100) 208 (100)  1536 (100) 64 (100) 787 (100) 685 (100)  
3 categories, N, (col %) 
- AAC = 0 & CAC = 0 
 
1246 (40) 
 
770 (49) 
 
211 (50) 
 
478 (50) 
 
81 (39) 
 
 
476 (31) 
 
26 (41) 
 
279 (35) 
 
171 (25) 
 
- AAC > 0 & CAC = 0 982 (32) 432 (27) 123 (29) 252 (27) 57 (27) .005 550 (36) 15 (23) 283 (36) 252 (37) <.001 
- CAC > 0, regardless of AAC 889 (29) 379 (24) 92 (22) 217 (23) 70 (34)  510 (33) 23 (36) 225 (29) 262 (38)  
2 categories (binary outcome) 
- AAC > 0, N, (% compared to AAC=0) 
 
1663 (53) 
 
679 (43) 
 
187 (44) 
 
394 (41) 
 
98 (47) 
 
.3 
 
984 (64) 
 
32 (50) 
 
473 (60) 
 
479 (70) 
 
<.001 
- CAC > 0, N, (% compared to CAC=0) 889 (29) 379 (24) 92 (22) 217 (23) 70 (34) .002 510 (33) 23 (36) 225 (29) 262 (38) <.001 
- AAC > 0 or CAC > 0, N, (% compared 
to AAC=0 & CAC=0) 
1871 (60) 811 (51) 215 (50) 469 (50) 127 (61) .01 1060 (69) 38 (59) 508 (65) 514 (75) <.001 
 
†  p-values from χ2 test across categories. 
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Table 3. Association between lifetime exposure to marijuana and measures of subclinical 
atherosclerosis and among never/ever tobacco users, CARDIA, year 25* 
 
 Never tobacco smokers Ever tobacco smokers 
 
Unadjusted 
models (N=1581)‡  
Multivariate 
adjusted models 
(N=1562)§ 
Unadjusted models 
(N=1536)‡ 
Multivariate 
adjusted models 
(N=1502)§ 
Cumulative exposure in 
marijuana-years 
    
(a) AAC =0 & CAC =0 Ref. Ref. Ref. Ref. 
(b) AAC >0 & CAC =0 
- At 0.5 marijuana-years 
 
1.00 (0.88 to 
1.13) 
 
0.97 (0.82 to 1.14) 
 
1.19 (1.09 to 1.32) 
 
1.18 (1.04 to 1.34) 
- At 1 marijuana-years 1.00 (0.80 to 
1.26) 
0.95 (0.70 to 1.28) 1.39 (1.17 to 1.66) 1.36 (1.07 to 1.71) 
- At 5 marijuana-years 1.09 (0.68 to 
1.74) 
0.98 (0.51 to 1.88) 2.11 (1.47 to 3.03) 1.97 (1.21 to 3.21) 
- At 10 marijuana-years 1.25 (0.72 to 
2.17) 
1.20 (0.58 to 2.48) 1.92 (1.35 to 2.75) 1.78 (1.10 to 2.89) 
p-value ll 0.7 0.6 <0.001 0.02 
(c) CAC >0 regardless of 
AAC 
- At 0.5 marijuana-years 
 
1.18 (1.05 to 
1.33) 
 
0.99 (0.84 to 1.18) 
 
1.22 (1.10 to 1.34) 
 
1.15 (0.99 to 1.33) 
- At 1 marijuana-years 1.37 (1.10 to 
1.69) 
1.00 (0.73 to 1.36) 1.44 (1.20 to 1.72) 1.29 (0.98 to 1.69) 
- At 5 marijuana-years 2.33 (1.51 to 
3.63) 
1.17 (0.60 to 2.30) 2.42 (1.68 to 3.51) 1.83 (1.02 to 3.31) 
- At 10 marijuana-years 2.85 (1.74 to 
4.66) 
1.63 (0.81 to 3.29) 2.51 (1.76 to 3.58) 1.85 (1.05 to 3.26) 
p-value ll <0.001 0.2 <0.001 0.1 
Cumulative exposure in 
tobacco pack-years 
 
 
  
(b) AAC >0 & CAC =0 
- At 5 tobacco pack-years 
 
- 
 
- 
 
1.85 (1.54 to 2.21) 
 
1.90 (1.53 to 2.36) 
- At 10 tobacco pack-years - - 5.70 (3.96 to 8.20) 5.86 (3.64 to 9.45) 
- At 40 tobacco pack-years 
- - 9.63 (5.15 to 17.99) 
8.80 (4.25 to 
18.21) 
p-value ll   <0.001 <0.001 
(c) CAC >0 regardless of 
AAC 
- At 5 tobacco pack-years 
 
- 
 
- 
 
1.83 (1.52 to 2.21) 
 
1.93 (1.52 to 2.44) 
- At 10 tobacco pack-years 
- - 6.68 (4.58 to 9.73) 
6.61 (3.92 to 
11.14) 
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- At 40 tobacco pack-years 
- - 18.19 (9.8 to 33.64) 
12.54 (5.92 to 
26.55) 
p-value ll   <0.001 <0.001 
 
Abbreviations: IPCW: Inverse probability of censoring weighting; Ref.: Reference 
* Cumulative exposure to marijuana expressed in ‘marijuana-years’, with 1 marijuana-year of 
exposure equivalent to 365 days of marijuana use.(see Methods).  
‡ Multinomial logistic regression models with three categories of subclinical atherosclerosis: 1) no 
AAC and no CAC; 2) any AAC and no CAC; and, 3) CAC, regardless of AAC as the outcome and 
cumulative exposure to marijuana or tobacco smoking modeled as restricted cubic splines, stratified 
by history of exposure to tobacco smoking (Methods). 
§ Model described in ‡ additionally adjusted for age, race, sex, study site, years of education, 
cumulative and current exposure to licit and illicit substances such as cigarette smoking, alcohol, 
cocaine, amphetamines and heroin, exposure to passive smoking, cardiovascular risk factors, 
physical activity, BMI, depression symptoms, and diabetes (Methods). Analyses weighted by the 
inverse probability of censoring (IPCW) to address potential bias by informative censoring 
(eMethods). 
ll p-values obtained by Wald-test across the entire variable contrasting the reference value to the 
AAC/CAC category.   
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Table 4. Estimated ORs from multivariate adjusted model at five marijuana-years of exposure 
 
 Never tobacco  smokers Ever tobacco  smoker
s 
 OR (95% CI) at 5 
marijuana-years 
P-value OR (95% CI) at 5 
marijuana-years 
P-value 
Multinomial model (3 
categories) 
    
- AAC =0 & CAC =0 Ref.  Ref.  
- AAC >0 & CAC =0 0.98 (0.51 to 1.88) .9 1.97 (1.21 to 3.21) .007 
- CAC >0 regardless of AAC 1.17 (0.60 to 2.30) .6 1.83 (1.02 to 3.31) .04 
Logistic regressions (2 
categories) 
    
- AAC =0 regardless of CAC Ref.  Ref.  
- AAC >0 regardless of CAC 0.89 (0.53 to 1.52) .7 1.84 (1.18 to 2.08) .007 
- CAC =0 regardless of AAC Ref.  Ref.  
- CAC >0 regardless of AAC 1.20 (0.65 to 1.26) .6 1.18 (0.72 to 1.92) .5 
- AAC =0 & CAC =0 Ref.  Ref.  
- AAC >0 or CAC >0 1.07 (0.63 to 1.85) .8 1.91 (1.20 to 3.05) .006 
 
Note: Only participants with both AAC and CAC measures at year 25 included. Multivariate models 
stratified by history of tobacco smoking, adjusted for covariates potentially associated with marijuana 
and subclinical atherosclerosis: age, race, sex, study site, years of education, exposure to illicit and 
licit substances (cigarette smoking, alcohol, cocaine, amphetamines and heroin use, exposure to 
passive smoking), cardiovascular risk factors, physical activity, BMI, depression symptoms, and 
diabetes (Methods). Analyses weighted by the inverse probability of censoring (IPCW) to address 
potential bias by informative censoring (eMethods). 
 
 
